KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment

On December 17, 2025, Knowledge Ecology International (KEI) provided comments to the National Institutes for Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Tumor Infiltrating Lymphocytes for the Treatment of Cancer” (89 FR 95224) to… Continue Reading

Discussion Regarding a Proposal for a WTO Agreement for the Supply of Public Goods – 20 December 2024

Friday 20 December 2024 10:00am-11:00am ET // 16:00-17:00 CET Knowledge Ecology International will host a discussion regarding a proposal for a World Trade Agreement on the supply of public goods. The purpose of the proposal is to expand the supply… Continue Reading

KEI Comments on NIH Exclusive License to Columbia for Ebola Technology

On December 5, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Peptides and Peptide Microarrays for Detection and Differentiation of Antibody Responses to Ebola… Continue Reading

KEI Letter to USPTO on WIPO Design Law Treaty Federal Funding Disclosure Issue

Knowledge Ecology International (KEI) has sent a letter to Katherine Vidal, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO) concerning an issue in Article 3 of the the World Intellectual Property… Continue Reading

KEI Comments on NIH Exclusive License to Autala for Autoimmune Treatment

On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading

KEI Joins Amicus Brief in CIR v. Dept of Labor case on FOIA and Transparency of Government Records

On July 17, 2024, Knowledge Ecology International (KEI) joined Universities Allied for Essential Medicines, Dr. Christopher Morten, and Dr. Reshma Ramachandran in submitting an amicus brief in the case of the Center for Investigative Reporting, et al. v. United States… Continue Reading

KEI Comments on NIH License to McSAF for Antibody-Drug Conjugates for Cancer

Knowledge Ecology International (KEI) offered the following comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors” (89 FR 40495) to McSAF Inside Oncology SAS (McSAF).… Continue Reading

KEI Comments on NIH Exclusive License to INTcRON

On Tuesday June 4, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding “Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer” (89 FR 43859) to… Continue Reading